![[Leu15]-Gastrin I (human)](https://file.medchemexpress.com/product_pic/hy-p2671.gif "Click to View [Leu15]-Gastrin I (human) Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
148 Results for "
CCK
" in MedChemExpress (MCE) Product Catalog:
Products (148)
148 Results for "CCK" in MCE Product Catalog:
4119
4119 Publications Verification
Cat. No.: HY-K0301
Cell Counting Kit-8 (CCK-8) allows sensitive colorimetric assays for the determination of cell viability in cell proliferation and cytotoxicity assays.The 5 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.
17
17 Cited Publications
Cat. No.: HY-P1097
CAS No.: 10047-33-3
Target:
Research Areas:
6
6 Cited Publications
Synonyms: L-364,718; MK-329
Target:
Research Areas:
Devazepide (L-364,718) is a potent, competitive, selective and orally active nonpeptide antagonist of cholecystokinin (CCK) receptor, with IC50s of 81 pM, 45 pM and 245 nM for rat pancreatic, bovine gallbladder and guinea pig brain CCK receptors, respectively. Devazepide (L-364,718) is effective for gastrointestinal disorders .
4
4 Cited Publications
Cat. No.: HY-P0093
CAS No.: 25126-32-3
Synonyms: Cholecystokinin octapeptide; CCK-8; SQ19844
4
4 Cited Publications
Cat. No.: HY-P0093A
CAS No.: 70706-98-8
Synonyms: Cholecystokinin octapeptide ammonium; CCK-8 ammonium; SQ19844 ammonium
4
Target:
Research Areas:
Loxiglumide is a cholecystokinin (CCK-1) receptor antagonist.
2
Target:
Research Areas:
2
2 Cited Publications
Synonyms: Cholecystokinin-33(human); CCK-33(human)
Target:
Research Areas:
2
2 Cited Publications
Target:
Research Areas:
L-365260 is an orally active and selective antagonist of non-peptide gastrin and brain cholecystokinin receptor (CCK-B), with Kis of 1.9 nM and 2.0 nM, respectively. L-365260 interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors. L-365260 can enhance Morphine analgesia and prevents Morphine tolerance .
2
2 Cited Publications
Target:
Research Areas:
YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively . YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo .
2
2 Cited Publications
Synonyms: UCL-1397 oxalate
Target:
Research Areas:
Butabindide (UCL-1397) oxalate is a potent, selective tripeptidvl peptidase II (TPP II) inhibitor with Ki values of 7 nM and 10 μM for TPP II and TPP I, respectively. Butabindide oxalate inhibits TPP II to protect CCK-8 against inactivation .
2
2 Cited Publications
Cat. No.: HY-P0196A
CAS No.: 171486-94-5
Synonyms: CCK Octapeptide, desulfated TFA
Target:
Research Areas:
2
2 Cited Publications
Cat. No.: HY-106840A
Purity: 99.75%
Target:
Research Areas:
L-365260 hemihydrate is an orally active and selective antagonist of non-peptide gastrin and brain cholecystokinin receptor (CCK-B), with Kis of 1.9 nM and 2.0 nM, respectively. L-365260 hemihydrate interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors .
2
2 Cited Publications
Cat. No.: HY-P1800A
Target:
Research Areas:
1
Target:
Research Areas:
Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities .
1
1 Cited Publications
Synonyms: Netazepide; YF 476; YM-220
Target:
Research Areas:
Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent, highly selective and orally active Gastrin/CCK-B antagonist with an IC50 value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC50 of 502 nM . Sograzepide (Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human Gastrin/CCK-B receptors, with Ki values of 0.068, 0.62 and 0.19 nM, respectively .
1
Target:
Cholecystokinin Receptor Ephrin Receptor Interleukin Related VEGFR HIF/HIF Prolyl-Hydroxylase Akt
Research Areas:
Nastorazepide (Z-360) is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide inhibits the specific binding of [ 3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide has antitumor activity against pancreatic cancer. Nastorazepide inhibits colorectal cancer liver metastasis and relieves pain .
1
1 Cited Publications
Synonyms: Cholecystokinin tetrapeptide; CCK-4
Target:
Research Areas:
1
1 Cited Publications
Target:
Research Areas:
Proglumide sodium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide sodium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide sodium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide sodium also has antiepileptic and antioxidant activities .
1
1 Cited Publications
Cat. No.: HY-P2671
CAS No.: 39024-57-2
Target:
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
